Intellia Therapeutics (NASDAQ:NTLA) Price Target Cut to $60.00 by Analysts at Oppenheimer

Intellia Therapeutics (NASDAQ:NTLA) had its price target lowered by Oppenheimer from $70.00 to $60.00 in a research note released on Monday,Benzinga reports. Oppenheimer currently has an outperform rating on the stock.

NTLA has been the subject of a number of other research reports. Stifel Nicolaus lowered their price target on Intellia Therapeutics from $80.00 to $64.00 and set a “buy” rating for the company in a research report on Wednesday, September 11th. Chardan Capital cut their price target on shares of Intellia Therapeutics from $94.00 to $88.00 and set a “buy” rating on the stock in a report on Thursday, October 24th. Robert W. Baird dropped their price objective on shares of Intellia Therapeutics from $24.00 to $18.00 and set a “neutral” rating on the stock in a report on Friday, October 25th. Citigroup reduced their target price on shares of Intellia Therapeutics from $25.00 to $19.00 and set a “neutral” rating for the company in a report on Friday, October 25th. Finally, The Goldman Sachs Group lowered their price target on shares of Intellia Therapeutics from $31.00 to $20.00 and set a “neutral” rating on the stock in a report on Friday, October 25th. One investment analyst has rated the stock with a sell rating, five have given a hold rating, ten have given a buy rating and one has issued a strong buy rating to the company’s stock. According to MarketBeat.com, Intellia Therapeutics presently has an average rating of “Moderate Buy” and a consensus target price of $55.36.

Intellia Therapeutics Stock Down 3.2 %

NTLA opened at $16.11 on Monday. The company has a market cap of $1.64 billion, a P/E ratio of -2.96 and a beta of 1.81. The firm’s 50-day moving average price is $18.97 and its 200-day moving average price is $22.18. Intellia Therapeutics has a 52-week low of $13.95 and a 52-week high of $34.87.

Intellia Therapeutics (NASDAQ:NTLA) last posted its quarterly earnings results on Thursday, November 7th. The company reported ($1.34) earnings per share (EPS) for the quarter, topping analysts’ consensus estimates of ($1.37) by $0.03. The company had revenue of $9.10 million during the quarter, compared to analysts’ expectations of $8.28 million. The company’s quarterly revenue was down 24.1% on a year-over-year basis. During the same period in the prior year, the business posted ($1.38) EPS. On average, research analysts anticipate that Intellia Therapeutics will post -5.13 EPS for the current fiscal year.

Insider Buying and Selling at Intellia Therapeutics

In other news, CAO Michael P. Dube sold 2,012 shares of the business’s stock in a transaction dated Wednesday, October 2nd. The shares were sold at an average price of $19.01, for a total transaction of $38,248.12. Following the completion of the sale, the chief accounting officer now owns 47,012 shares of the company’s stock, valued at $893,698.12. The trade was a 0.00 % decrease in their ownership of the stock. The transaction was disclosed in a document filed with the Securities & Exchange Commission, which is available at this link. Insiders own 3.20% of the company’s stock.

Institutional Trading of Intellia Therapeutics

Several large investors have recently made changes to their positions in the company. Allspring Global Investments Holdings LLC grew its holdings in shares of Intellia Therapeutics by 9.2% during the first quarter. Allspring Global Investments Holdings LLC now owns 8,894 shares of the company’s stock worth $245,000 after buying an additional 750 shares in the last quarter. SG Americas Securities LLC acquired a new stake in Intellia Therapeutics in the 1st quarter valued at about $160,000. Swiss National Bank lifted its stake in Intellia Therapeutics by 1.3% in the 1st quarter. Swiss National Bank now owns 167,900 shares of the company’s stock worth $4,619,000 after purchasing an additional 2,200 shares in the last quarter. Headlands Technologies LLC acquired a new position in shares of Intellia Therapeutics during the 1st quarter worth approximately $224,000. Finally, ProShare Advisors LLC boosted its holdings in shares of Intellia Therapeutics by 11.9% during the 1st quarter. ProShare Advisors LLC now owns 23,235 shares of the company’s stock worth $639,000 after purchasing an additional 2,466 shares during the last quarter. 88.77% of the stock is currently owned by hedge funds and other institutional investors.

Intellia Therapeutics Company Profile

Intellia Therapeutics, Inc, a genome editing company, focuses on the development of curative therapeutics. The company's in vivo programs include NTLA-2001, which is in Phase 1 clinical trial for the treatment of transthyretin amyloidosis; NTLA-2002 for the treatment of hereditary angioedema; and NTLA-3001 for alpha-1 antitrypsin deficiency associated lung disease.